The term “cannabinoids” originally described bioactive constituents of the plant Cannabis sativa, a plant that can grow wild in mild, tropical climates around the world. For centuries, the cannabis ingredients were used traditionally for their medicinal purpose but also for their recreational properties; however, only since the 1940s have cannabinoids been purified from cannabis plants. Then, in the 1980s, researchers found the first cannabinoid receptor and soon after it was discovered that humans create cannabinoid-like chemical within our own bodies called endocannabinoids.
What do Endocannabinoids do?
The two endocannabinoids humans have in their bodies are called CB1 and CB2 receptors. CB1 is mainly found on cells in the nervous system, including certain areas of the brain and the ends of nerves throughout the body, while CB2 receptors are mainly found in cells from the immune system. CB1 receptors are responsible for the psychoactive effects; know as a ‘high’ after using cannabis.
Scientists have found that endocannabinoids and cannabinoid receptors are involved in a wide array of bodily functions, including helping to control brain, nerve memory, pain, energy metabolism, heart function, the immune system and even reproduction. Because of their involvement in so many systems, they’re function is also connected to a vast range of illnesses, from cancer to neurodegenerative diseases.
For those scientists interested in CBD cancer research and its affects on the endocannabinoids in the human body, they are utilizing CBD in clinical trials to learn if it is possible and effective to incorporate CBD into clinical care for certain medical conditions and diseases.
Why Are We Hearing so Much About CBD Now?
The legalization of marijuana in many states, and in our neighboring country, Canada, has triggered interest in marijuana-related products. An interest in CBD and research about its uses and efficacy are likely to increase in the coming years.
At this time, by federal law, the possession of Cannabis is illegal in the United States, except within approved research settings; however, a growing number of states, territories, and the District of Columbia have enacted laws to legalize its medical use with strict conditions.
The U.S. Food and Drug Administration has not approved Cannabis as a treatment for cancer or any other medical condition. This may all change if the 2018 Farm Bill is passed.
The Farm Bill
In December of 2018, a five-year Farm Bill was passed by both the United States House and Senate of Congress. About eighty percent of the money in the bill funds the SNAP or Supplemental Nutrition Assistance Program. This has led many to refer to the bill as a Food Bill rather than a Farm Bill.
Also included in the Farm bill is an important piece of this legislature will greatly affect the CBD industry. The Farm Bill includes legislation that legalizes industrial hemp. CBD is derived from hemp, which will be legal in all 50 states if President Trump now signs the 2018 Farm Bill. This would be a significant development for producers of cannabidiol, researchers and the American people.
About Diverse Biotech, Inc.
Diverse Biotech Inc. is an innovative, clinical-stage biopharmaceutical research company, committed to discovering and developing novel therapeutics from its proprietary cannabinoid product platform.
For more information on Diverse Biotech or its Cannabinoid (CBD) clinical trials, use in the treatment of specific types of malignancies related to glioblastoma, myeloma, gastrointestinal, and breast cancer, when administered in conjunction with Standard of Care, please contact Diverse Biotech by phone at 407-776-9217 or visit the company’s headquarters at 805 S. Kirkman Rd, Suite 202, Orlando, Florida 32811.